Research Article

Development of Innovative Polymer-Based Matricial Nanostructures for Ritonavir Oral Administration

Figure 2

Mean diameter by volume (a) and by number of particles (b), size distribution values (Span) by volume (c) and by number of particles (d), zeta potential (e), pH (f), and RIT content (g) of nanoparticles at times 0, 15, 30, and 60 days (NPR = nanoparticles containing ritonavir, RIT = ritonavir).
(a)
(b)
(c)
(d)
(e)
(f)
(g)